UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Pathobiology of Burkitt lymphoma

Authors
Jennifer R Brown, MD, PhD
Arnold S Freedman, MD
Jon C Aster, MD
Section Editor
Andrew Lister, MD, FRCP, FRCPath, FRCR
Deputy Editor
Alan G Rosmarin, MD

INTRODUCTION

Burkitt lymphoma (BL) is a highly aggressive B cell neoplasm characterized by the translocation and deregulation of the c-MYC gene on chromosome 8. Three distinct clinical forms of BL are recognized: endemic, sporadic, and immunodeficiency-associated. Although they are histologically identical and have similar clinical behavior, there are differences in epidemiology, clinical presentation, and genetic features between the three forms. (See "Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma", section on 'Clinical features'.)

BL and Burkitt leukemia (FAB L3 acute lymphoblastic leukemia) are classified as different manifestations of the same disease in the 2008 World Health Organization (WHO) classification of hematologic malignancies [1]. The WHO classification also recognizes the existence of tumors with features intermediate between BL and diffuse large B cell lymphoma, which remain difficult diagnostic challenges. (See "Classification of the hematopoietic neoplasms".)

The pathogenesis of BL will be discussed here. Information regarding the diagnosis and treatment of BL is presented separately. (See "Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma".)

CELL OF ORIGIN

BL is derived from germinal or post-germinal center B cells. The germinal or post-germinal center ancestry of these cells is principally supported by the identification of somatic mutations in the variable region of the immunoglobulin genes (IgV), which serve as a marker of germinal center transit, as well as the tumor cell immunophenotype. Some studies have demonstrated ongoing somatic mutation, a process that is normally restricted to germinal center B cells. (See "Normal B and T lymphocyte development" and "Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma", section on 'Other genetic abnormalities'.)

The different clinical subtypes of BL (ie, endemic, nonendemic, and immunodeficiency-related) likely arise from B cells at different stages of development. Specifically, Epstein Barr virus (EBV)-negative BLs show a low level of somatic hypermutation of their variable region heavy chain genes and no signs of antigen selection, whereas EBV-positive (generally endemic or AIDS-related) BLs have significantly higher levels of somatic hypermutation and evidence of antigen selection [2]. These findings suggest that EBV-negative BL may arise from an early centroblast, while EBV-positive BL may arise from a memory B cell or late germinal center B cell. This difference in cell of origin may also relate to the observed difference in c-MYC translocation breakpoints described below. Despite these differences, these clinical subtypes have many similarities in gene expression suggesting a common pathogenesis [3]. (See 'Chromosomal translocations' below.)

             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Apr 14 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.
  2. Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005; 106:1031.
  3. Piccaluga PP, De Falco G, Kustagi M, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood 2011; 117:3596.
  4. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18:3707.
  5. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol 2010; 149:484.
  6. Müller JR, Janz S, Goedert JJ, et al. Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men. Proc Natl Acad Sci U S A 1995; 92:6577.
  7. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991; 251:1211.
  8. Blackwood EM, Lüscher B, Eisenman RN. Myc and Max associate in vivo. Genes Dev 1992; 6:71.
  9. Gu W, Cechova K, Tassi V, Dalla-Favera R. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. Proc Natl Acad Sci U S A 1993; 90:2935.
  10. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22:2755.
  11. Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012; 151:68.
  12. Lovén J, Orlando DA, Sigova AA, et al. Revisiting global gene expression analysis. Cell 2012; 151:476.
  13. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21:297.
  14. Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993; 72:211.
  15. Zervos AS, Gyuris J, Brent R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 1993; 72:223.
  16. Walker W, Zhou ZQ, Ota S, et al. Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J Cell Biol 2005; 169:405.
  17. Calado DP, Sasaki Y, Godinho SA, et al. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol 2012; 13:1092.
  18. Stamm O, Latscha U, Janecek P, Campana A. Development of a special electrode for continuous subcutaneous pH measurement in the infant scalp. Am J Obstet Gynecol 1976; 124:193.
  19. Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell 1987; 49:161.
  20. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318:533.
  21. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354:2431.
  22. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354:2419.
  23. Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982; 79:7824.
  24. ar-Rushdi A, Nishikura K, Erikson J, et al. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science 1983; 222:390.
  25. Pelicci PG, Knowles DM 2nd, Magrath I, Dalla-Favera R. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1986; 83:2984.
  26. Neri A, Barriga F, Knowles DM, et al. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1988; 85:2748.
  27. Ramiro AR, Jankovic M, Callen E, et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 2006; 440:105.
  28. Robbiani DF, Deroubaix S, Feldhahn N, et al. Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma. Cell 2015; 162:727.
  29. Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 1987; 238:1272.
  30. Bhatia K, Huppi K, Spangler G, et al. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5:56.
  31. Gu W, Bhatia K, Magrath IT, et al. Binding and suppression of the Myc transcriptional activation domain by p107. Science 1994; 264:251.
  32. Dang CV. MYC on the path to cancer. Cell 2012; 149:22.
  33. Toujani S, Dessen P, Ithzar N, et al. High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma. PLoS One 2009; 4:e7089.
  34. Seegmiller AC, Garcia R, Huang R, et al. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol 2010; 23:909.
  35. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490:116.
  36. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44:1321.
  37. Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012; 44:1316.
  38. Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012; 22:167.
  39. Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999; 17:1558.
  40. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114:2273.
  41. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010; 34:327.
  42. Chene A, Donati D, Orem J, et al. Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Semin Cancer Biol 2009; 19:411.
  43. Parkin DM, Sitas F, Chirenje M, et al. Part I: Cancer in Indigenous Africans--burden, distribution, and trends. Lancet Oncol 2008; 9:683.
  44. Morrow RH Jr. Epidemiological evidence for the role of falciparum malaria in the pathogenesis of Burkitt's lymphoma. IARC Sci Publ 1985; :177.
  45. Aka P, Vila MC, Jariwala A, et al. Endemic Burkitt lymphoma is associated with strength and diversity of Plasmodium falciparum malaria stage-specific antigen antibody response. Blood 2013; 122:629.